Rhumbline Advisers trimmed its position in shares of Atrion Co. (NASDAQ:ATRI – Free Report) by 5.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,693 shares of the medical instruments supplier’s stock after selling 366 shares during the quarter. Rhumbline Advisers owned approximately 0.38% of Atrion worth $3,028,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in ATRI. Quadrant Capital Group LLC acquired a new stake in Atrion in the 4th quarter valued at $36,000. EntryPoint Capital LLC acquired a new stake in Atrion during the 1st quarter worth $91,000. Comerica Bank boosted its stake in Atrion by 60.9% during the 1st quarter. Comerica Bank now owns 415 shares of the medical instruments supplier’s stock worth $192,000 after purchasing an additional 157 shares during the last quarter. Jump Financial LLC acquired a new stake in Atrion during the 4th quarter worth $234,000. Finally, Principal Financial Group Inc. acquired a new stake in Atrion during the 1st quarter worth $280,000. 66.19% of the stock is owned by hedge funds and other institutional investors.
Atrion Price Performance
Shares of NASDAQ:ATRI opened at $459.92 on Wednesday. The firm has a market capitalization of $809.46 million, a PE ratio of 43.23 and a beta of 0.69. The firm’s 50-day moving average is $458.52 and its two-hundred day moving average is $443.84. Atrion Co. has a 1 year low of $274.98 and a 1 year high of $503.24.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of Atrion in a research report on Wednesday, September 11th. They set a “sell” rating on the stock.
Read Our Latest Report on Atrion
Atrion Profile
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More
- Five stocks we like better than Atrion
- What is a Bond Market Holiday? How to Invest and Trade
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- How is Compound Interest Calculated?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.